Dr. Sonya Kashyap is a Clinical Assistant Professor, Department of Obstetrics & Gynaecology and an Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California at San Francisco (UCSF), USA.

Dr. Kashyap completed her undergraduate training at Queen’s University followed by medical school, residency in obstetrics and gynecology and a MSc in Epidemiology at the University of Ottawa. She then completed her fellowship in Reproductive Endocrinology and Infertility at the renowned Ron Perlman Center for Reproductive Medicine at Cornell University Medical College in Manhattan under the mentorship of Dr Zev Rosenwaks.

In 2010, Dr. Kashyap moved to Vancouver from UCSF to work at Genesis Fertility Centre. Her passion is optimizing in vitro fertilization (IVF) outcomes and success rates for women and couples through revolutionary science and compassionate care. At Genesis, Dr. Kashyap introduced programs such as egg and embryo vitrification, trophectoderm biopsy, comprehensive chromosomal screening and non-invasive embryo screening through Early Embryonic Viability Assessment (Eeva). Dr. Kashyap has been an invited speaker on topics such as patient decision making in IVF, healthy singleton births, maternal outcomes after IVF, fertility preservation for cancer patients, and the impact of fertility drugs on breast and ovarian cancer.

Research Interests/Skills

Dr. Kashyap’s interests are assisted reproductive technologies (ARTs), IVF, fertility preservation, multiple gestation, insulin sensitizing agents, ovarian cancer after fertility.


Kashyapm, S., Wells, G. A. , Davis,  O. K. , Williams-Pittman,  M. A. , Rosenwaksm, Z. (2014).  A prospective randomized controlled pilot study of aromatase inhibitors to improve ovarian response in poor responders undergoing in-vitro fertilization. Fertility & Sterility. Submitted with revisions

Kashyap, S., Wells, G. A., Rosenwaks, Z. (2014). Randomized controlled trials in ART- how when, and why? Fertility and Sterility. Submitted

Kashyap, S., Liu, H-C., Davis, O. K., Rosenwaks, Z. (2014). Subtle alterations in normal thyroid function may affect IVF implantation rates. Journal of Clinical Epidemiology & Metabolism. Submitted


April 2008-Present, CFI/CIHR Regional/National Clinical Research Initiatives Perinatal outcomes, PI:W Fraser, Co-I: S Kashyap, $9,000,000

July 1, 2006-July 1, 2011, Ontario Women’s Health Council /Canadian Institutes of Health Research and Institute of Gender and Health New Investigator Award, PI, $250,000 for 5 years

July 1, 2006-September 30, 2008, CIHR, A randomized Controlled trial of GnRH agonists for fertility preservation in oncology patients, PI, $257,145 for 3 yrs

December 2008, Research Allocation Resource Program Grant, PI, $35,000, UCSF


A randomized controlled trial of gonadotropin releasing hormone agonist (gnRHa) for fertility preservation in oncology patients Completed
July, 2006December, 2011

Medical therapy (GnRHa) to suppress ovarian function, preserve ovarian reserve and fertility is an encouraging and simple option that has never been adequately studied. We propose to evaluate such therapy through a randomized controlled trial and obtain a definitive answer to the question �Do GnRH agonists preserve ovarian function in women of reproductive age undergoing menopause-inducing chemotherapy?� The number of girls and young women of reproductive age surviving radiation and chemotherapy for cancer treatment is increasing. Issues of survivorship and quality of life therefore become increasingly relevant. A significant concern is preservation of reproductive potential. Current methods available for fertility preservation and their success rates are hotly debated on the basis of scant evidence. The only efficient, proven technologies for fertility preservation include embryo freezing after in-vitro fertilization and egg donation for women rendered prematurely menopausal. Experimental therapies are still highly inefficient and invasive and include: ovarian freezing, egg freezing, and in-vitro maturation of immature eggs. Unfortunately, assisted reproductive technologies are expensive and may not be widely available. A need exists to evaluate medical therapy as a viable, less expensive and simpler option.